Following the market close, the Somerset, NJ-based drug delivery technology manufacturer reported adjusted earnings of 52 cents per share, which fell short of analysts' estimates of 53 cents per share.
Revenue for the quarter was $532.2 million, higher than Wall Street's projections of $502.2 million.
For the full year, Catalent posted adjusted earnings of $1.22 per share on revenue of $1.85 billion. Wall Street was looking for earnings of $1.20 per share on revenue of $1.82 billion.
CEO John Chiminski said that 2016 was "clearly a challenging year overall" for Catalent. But he added that he was "encouraged" by the company's fourth quarter results.
"We continue to believe that ongoing market consolidation and strong demand for fewer, bigger, and better suppliers in our dynamic industry positions us well for future organic growth," Chiminski stated.
In fiscal 2017, the company sees revenue in the range of $1.92 billion to $2 billion. Analysts are expecting revenue of $1.92 billion for the full year.
About 1.1 million of the company's shares traded today vs. its 30-day average of about 665,000 shares.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rated this stock as a "hold" with a ratings score of C.
The company's strengths can be seen in multiple areas, such as its notable return on equity, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and generally higher debt management risk.
You can view the full analysis from the report here: CTLT